Vor Bio Drug Slows Kidney Decline in Study
Vor Bio reports its experimental drug telitacicept successfully slowed kidney function decline and reduced disease progression risk in a late stage study of IgA nephropathy patients. The treatment preserved kidney function over two years and significantly lowered urine protein levels compared to placebo.
Xurve View
Insights:
Xurve View
VOR BIOPHARMA INC reported that its experimental drug telitacicept slowed kidney function loss by 89% in a late-stage study. The therapy targets IgA nephropathy patients, offering a new avenue to prevent renal failure. Preserving organ performance over extended treatment periods addresses a major unmet need in nephrology.
